Pharmaceutical care in the treatment of menstrual cycle disorders among women of reproductive age: rational choice and use of drugs

Pharmaceutical care in the treatment of menstrual cycle disorders among women of reproductive age: rational choice and use of drugs DOI: https://doi.org/10.32352/0367-3057.4.23.09Keywords: menstrual cycle, women, pharmaceutical care, drug interactionAbstract In the structure of gynecological diseases, menstrual cycle disorders are for up to 60% and are the most common problem among women of reproductive age. Disorders of menstrual function can be caused by hormonal imbalance, endocrine system diseases, stress, hypovitaminosis, and excessive physical exertion. Changing of the menstrual cycle phases in the future may prevent normal fertilization, therefore it is necessary to receive appropriate pharmacotherapy in a timely manner, which is aimed to correct the main and accompanying pathological conditions for normalizing the reproductive function of women. The aim of the work – justification of the feasibility of developing pharmaceutical care for menstrual cycle disorders among women of reproductive age. The pharmacotherapy courses of 133 women aged 18 to 40 who were consulted by gynecologist at the «Kyiv City Maternity Hospital No. 5» and had menstrual cycle disorders were analyzed. Then, a questionnaire was carried out, in which 115 women took part. It was established that the pharmacotherapy courses that included more than 5 drugs and contained hormonal agents had high risks of interaction. In addition, herbal remedies, biologically active supplements, and vitamins are often used to treat menstrual disorders. According to the results of a sociological study, a high frequency of menstrual cycle disorders was found among women of reproductive age, the manifestations of which were delayed menstruation (66.6%), the appearance or intensification of a pain syndrome (52.2%), a change in menstruation (27.8%), etc. It has been established that more than 40% of women apply to self-prescription and self-treatment of menstrual cycle disorders. While 12% do not use the drugs for the normalization of menstrual function that was recommended by the doctor. In addition, 20 women who received treatment noted the appearance of side effects, such as headache, fatigue, irritability, changes in body weight, and swelling. The interaction between the gynecologist-pharmacist-patient is important to ensure rational and safe pharmacotherapy in the treatment of menstrual cycle disorders among women. The pharmacist, through the provision of pharmaceutical care, implements special knowledge of clinical pharmacology regarding the peculiarities of the interaction of drugs, the regimen of taking medicine, and the prevention of adverse reactions that may increase the effectiveness of the treatment of menstrual disorders among women. References Kwak Y., Kim Y., Baek K. A. Prevalence of irregular menstruation according to socioeconomic status: A population-based nationwide cross-sectional study // PloS one. – 2019. – V. 14, N 3. – Р. e0214071. https://doi.org/10.1371/journal.pone.0214071 Madaminov M. Causes, symptoms, classification, treatment methods of menstrual cycle disorder // Sci. Innovation. – 2022 – V. 7, N 1. https://doi.org/10.5281/zenodo.7296389 Huhmann K. Menses Requires Energy: A Review of How Disordered Eating, Excessive Exercise, and High Stress Lead to Menstrual Irregularities // Clin. Therapeutics. – 2022 – V. 42, N 3. – Р. 401–407. https://doi.org/10.1016/j.clinthera.2020.01.016 Demir O., Sal H., Comba C. Triangle of COVID, anxiety and menstrual cycle // J. Obstetrics Gynecology. – 2021 – V. 41, Iss. 8. – P. 1257–1261. https://doi.org/10.1080/01443615.2021.1907562 Rodríguez Quejada L., Toro Wills M. F., Martínez-Ávila M. C., Patiño-Aldana A. F. Menstrual cycle disturbances after COVID-19 vaccination // Women's Health. – 2022. – V. 18. https://doi.org/10.1177/17455057221109375 Lebar V., Laganà A. S., Chiantera V. et al. The Effect of COVID-19 on the menstrual cycle: asystematic review // J. Clin. Med. ‒ 2022. – V. 11, Iss. 13. https://doi.org/10.3390/jcm11133800 Burlaka O. V., Vahnier V. O. Pytannia reproduktyvnoho zdorovia zhinok viiskovosluzhbovtsiv v aspekti stres-asotsiiovanykh dyshormonalnykh porushen // Viiskova medytsyna Ukrainy. – 2021. – T. 19, № 4. – S. 58–63. https://doi.org/10.32751/2663-0761-2019-04-08 Kolisova S. E. Do pytannia patohenezu porushennia menstrualnoho tsyklu// Klin. eksperyment. patolohiia. – 2015. – T. 54, № 4. – S. 66–68. Podolskyi V. V., Kozar Ya. V. Porushennia reproduktyvnoho zdorovia u zhinok fertylnoho viku yododefitsytnykh rehioniv Ukrainy // Akt. pytannia pediatrii, akusherstva ta hinekolohii. – 2009. – № 1. – S. 37–40. https://doi.org/10.11603/24116-4944.2009.1.9654 Saei Ghare Naz M., Rostami Dovom M., Ramezani Tehrani F. The menstrual disturbances in endocrine disorders: anarrative review // Int. J. Endocrinol. Metab. – 2020. – V. 18, N 4. – Р. e106694. https://doi.org/10.5812/ijem.106694 Malanchuk O., Sharhorodska Ye., Shkolnyk O. Otsinka faktoriv ryzyku perynatalnoi patolohii u zhinok iz porushenniam menstrualnoi funktsii // Bukovynskyi med. visn. – 2021. – T. 98, № 2. – S. 75–81. https://doi.org/10.24061/2413-0737.XXV.2.98.2021.12 Bahrami A., Avan A., Sadeghnia H. R. et al. High dose vitamin D supplementation can improve menstrual problems, dysmenorrhea, and premenstrual syndrome in adolescents // Gynecol. Endocrinol. – 2018. – V. 34, N 8– P. 659–663. https://doi.org/10.1080/09513590.2017.1423466 Aguilar-Aguilar E. Menstrual disorders: what we know about dietary-nutritional therapy // Nutricion Hospitalaria. – 2021. – N 2. – P. 52–56. https://doi.org/10.20960/nh.03358 Tiong H. Y., Huang P., Xiong S. et al. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models // Mol. Pharm. – 2014. – V. 11, N 7. – P. 1933‒1948. https://doi.org/10.1021/mp400720w Zhabitska L. A. Syndrom polikistoznykh yaiechnykiv: indyvidualizovanyi pidkhid do likuvannia (ohliad literatury) // Reproduktyvna endokrynolohiia. – 2020. – T. 54, № 4. – S. 89–94. DrugBank. Levothyroxine. – URL: https://www.drugbank.ca/drugs/DB00451 Wen Z. P., Yang R. X., Feng X. J. et al. The interaction of aspirin and ethinylestradiol in human liver microsomes // Eur. J. Clin. Pharmacol. – 2009. – V. 65, N 10. – P. 983–990. https://doi:10.1007/s00228-009-0683-3 Van der Pas R., Hofland L. J., Hofland J. et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro // J. Endocrinol. – 2012. – V. 215, N 3. – P. 403–412. https://doi.org/10.1530/JOE-12-0310 Liu H. C., Goldenberg A., Chen Y. et al. Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approach // J. Pharmacol. Exp. Ther. – 2016. – V. 359, N 1. – P. 215–229. https://doi.org/10.1124/jpet.116.232660 National Institute for Health and Care Excellence. Acne vulgaris: management / Clinical guideline [CG 17]. ‒ 2018. – URL: https://www.nice.org.uk/guidance/cg17 Alkoudsi K. T., Al-Qudah R., Basheti I. A. Assessing the effectiveness of a pharmaceutical care service on the quality of life of women with polycystic ovarian syndrome living in war and non-war countries // Journal of Evaluation in Clinical Practice. – 2020. – V. 26, N 5. – Р. 1467–1477. https://doi.org/10.1111/jep.13310 Suaidi M. T., Wong P. K., Mohd Tahir N. A., Chua E. W. Community Pharmacists' Knowledge, Attitude, and Practice in Providing Self-Care Recommendations for the Management of Premenstrual Syndrome // Medicina (Kaunas, Lithuania). – 2020. – V. 56, N 4. – Р. 181. https://doi.org/10.3390/medicina56040181 Almanasef M., Alqarni H. Self-care strategies for the management of primary dysmenorrhea among young women in Asir region, Saudi Arabia: a cross-sectional study // Eur. Rev. Med. Pharmacol. Sci. – 2023. – V. 27, N 1. – Р. 172–178. https://doi.org/10.26355/eurrev_202301_30869